Skip to main content

Guttmacher Institute

Donate Now

Highlights

  • Roe v. Wade in Peril
  • COVID-19 impact
  • Reproductive Health Impact Study
  • Adding It Up
  • Abortion Worldwide
  • Guttmacher-Lancet Commission
  • U.S. policy resources
  • State policy resources
  • State legislation tracker

Reports

  • Global
  • U.S.

Articles

  • Global research
  • U.S. research
  • Policy analysis
  • Guttmacher Policy Review
  • Op-eds & external blogs

Fact Sheets

  • Global
  • U.S.
  • U.S. State Laws and Policies

Data & Visualizations

  • Data center
  • Infographics
  • Public-use data sets

Peer-Reviewed Journals

  • International Perspectives on Sexual and Reproductive Health
  • Perspectives on Sexual and Reproductive Health

Global

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

U.S.

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

Our Work By Geography

  • Global
  • Africa
  • Asia
  • Europe
  • Latin America & the Caribbean
  • Northern America
  • Oceania

Who We Are

  • About
  • Staff
  • Board
  • Job opportunities
  • History
  • Contact
  • Conflict of Interest Policy

Media

  • Media office
  • News releases

Support Our Work

  • Make a gift today
  • Monthly Giving Circle
  • Donate stock or securites
  • Guttmacher Legacy Circle
  • Financials
  • Annual Report

Awards and Scholarships

  • Darroch Award
  • Richards Scholarship
  • Bixby Fellowship

Search form

Good reproductive health policy starts with credible research

 

Connect With Us

  • Facebook
  • Instagram
  • Twitter
  • Email
Guttmacher Institute

Good reproductive health policy starts with credible research

 

Donate Now

Connect With Us

  • Facebook
  • Instagram
  • Twitter
  • Email

Highlights

  • Roe v. Wade in Peril
  • COVID-19 impact
  • Reproductive Health Impact Study
  • Adding It Up
  • Abortion Worldwide
  • Guttmacher-Lancet Commission
  • U.S. policy resources
  • State policy resources
  • State legislation tracker

Reports

  • Global
  • U.S.

Articles

  • Global research
  • U.S. research
  • Policy analysis
  • Guttmacher Policy Review
  • Op-eds & external blogs

Fact Sheets

  • Global
  • U.S.
  • U.S. State Laws and Policies

Data & Visualizations

  • Data center
  • Infographics
  • Public-use data sets

Peer-Reviewed Journals

  • International Perspectives on Sexual and Reproductive Health
  • Perspectives on Sexual and Reproductive Health

Global

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

U.S.

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

Our Work By Geography

  • Global
  • Africa
  • Asia
  • Europe
  • Latin America & the Caribbean
  • Northern America
  • Oceania

Who We Are

  • About
  • Staff
  • Board
  • Job opportunities
  • History
  • Contact
  • Conflict of Interest Policy

Media

  • Media office
  • News releases

Support Our Work

  • Make a gift today
  • Monthly Giving Circle
  • Donate stock or securites
  • Guttmacher Legacy Circle
  • Financials
  • Annual Report

Awards and Scholarships

  • Darroch Award
  • Richards Scholarship
  • Bixby Fellowship

Search form

June 30, 2016 Infographic

Twice as many abortion patients are eligible for medication abortion following the 2016 FDA label change

Twice as many abortion patients are eligible for medication abortion following the 2016 FDA label change

Terms of Use

The Guttmacher Institute encourages you to share this infographic freely to ensure that the debate is informed by facts, not misinformation.

Sources

Special tabulations of data from Centers for Disease Control and Prevention, Abortion surveillance—United States, 2012, Morbidity and Mortality Weekly Report, 2015, Vol. 64, No. SS-10.

PDF icon Download PDF of Graphic

Share

FacebookTwitterEmail

Read More

Infographic

The overall number of U.S. abortions continues to decline, while the proportion that are medication abortion increases

Infographic

Abortion has shifted earlier within the first trimester

News in Context

The Public Health Implications of the FDA Update to the Medication Abortion Label

Blog / Letter / Op-ed

The Public Health Implications of the FDA Update to the Medication Abortion Label

Health Affairs Blog

Topic

United States

  • Abortion

Geography

  • Northern America: United States
    • Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming
Guttmacher Institute
Reproductive rights are under attack. Will you help us fight back with facts?
Donate Now
Follow Guttmacher:

Connect With Us

  • Facebook
  • Instagram
  • Twitter
  • YouTube
  • LinkedIn

Footer Menu

  • Privacy Policy
© 2022 Guttmacher Institute. The Guttmacher Institute is registered as a 501(c)(3) nonprofit organization under the tax identification number 13-2890727. Contributions are tax deductible to the fullest extent allowable.

Get Our Updates